Fischer Medical Ventures Ltd confirmed its investment and collaboration with Bio Angle Vacs Sdn Bhd (BAV), a leading Biotechnology company in Malaysia that develops, manufactures and distributes vaccines to small and large-scale farming owners worldwide; focusing on health and disease prevention for livestock and aquaculture.
Founded in 2013, BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods. Its flagship innovation, the Spray Technology Vaccine (STVAC) leverages advanced recombinant technology and intranasal administration to elicit both mucosal and systemic immune responses, demonstrating enhanced protection for small ruminants, especially goats and sheep, against bacterial infections with high mortality rates.
BAV’s STVAC intranasal spray method minimizes stress for animals, reduces costs and simplifies the vaccination process. STVAC is tested to enhance protection of goats and sheep from pneumonia, reducing mortality rates significantly to below 5%.
BAV have to date secured a total of USD 83 million annual sales contracts from China, Nigeria, Kenya, Chad, Uganda, Uzbekistan and Indonesia for its range of innovative, sought-after animal vaccines.
Fischer MV and BAV are planning to establish a production facility in India to serve the local and Middle Eastern markets where livestock populations are top on the world’s list.